Updated Long-Term Follow-Up From the Phase 1b BOT+BAL Study at ESMO GI 2026 – Agenus
oncodaily - Agenus shared a post on LinkedIn: “At ESMOGI26, Agenus will share updated long-term follow-up from the Phase 1b study evaluating botensilimab plus balstilimab (BOT+BAL) in patients with MSS metastatic colorectal […]
AI Summary: Updated follow‑up data presented for botensilimab plus balstilimab reveal meaningful and durable activity in microsatellite‑stable metastatic colorectal cancer, with especially encouraging outcomes in patients lacking active liver metastases. The Agenus combination, showcased at a major gastrointestinal oncology meeting, renews interest in immune strategies for historically refractory MSS disease.
- Agenus releases Phase 1b three-year BOT+BAL survival data (2)
- Clinical and community reaction: experts weigh in on BOT+BAL (3)
- ESMO GI: BOT+BAL benefits in patients without active liver metastases (3)
- All Other Stories